

## Press Release

# Daiichi Sankyo Announces New 5-year Business Plan (FY2021 - FY2025)

**Tokyo, Japan (April 5, 2021)** – Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) today announced its 5-year Business Plan for fiscal 2021 - 2025 (hereinafter, 5YBP).

### 1. 2030 Vision

The Daiichi Sankyo group of companies aspires to be an **“Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”** The Daiichi Sankyo group of companies aims to address the social issues that we are expected by society to solve through our business activities, such as the creation of innovative pharmaceuticals and efforts for achieving the SDGs, and we will challenge ourselves to continuously provide innovative solutions based on our strength: Science & Technology.

### 2. Outline of the 5YBP

To achieve the 2030 vision, we set the following four strategies as the pillars of the 5YBP, and identified the foundations to strengthen in order to support the execution of these strategies.

#### < Four strategic pillars >

Strategy 1: Maximize 3ADCs

Strategy 2: Profit growth for current business & products

Strategy 3: Identify and build pillars for further growth

Strategy 4: Create shared value with stakeholders

#### < Foundations to support strategy execution >

- Data-driven management through DX (digital transformation), and company-wide transformation through advanced digital technology
- Agile decision making through new global management structure

### 3. Financial Targets in FY2025

To achieve the 2030 Vision, the following targets are set for fiscal 2025.

Revenue	<b>1.6 Trillion JPY</b>
Oncology Revenue	<b>600.0 Billion JPY or more</b>
Operating profit ratio before R&D expenses	<b>40 %</b>
ROE	<b>16 % or more</b>
DOE <sup>1</sup>	<b>8 % or more</b>

### 4. Contents of the Full 5YBP

For the full 5YBP, please visit: [www.daiichisankyo.com/investors/library/materials/](http://www.daiichisankyo.com/investors/library/materials/).

#### About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: [www.daiichisankyo.com/](http://www.daiichisankyo.com/).

#### Media Contacts:

##### Japan:

Koji Ogiwara  
[ogiwara.koji.ay@daiichisankyo.co.jp](mailto:ogiwara.koji.ay@daiichisankyo.co.jp)

##### Investor Relations Contact:

[DaiichiSankyoIR@daiichisankyo.co.jp](mailto:DaiichiSankyoIR@daiichisankyo.co.jp)

Masashi Kawase  
[kawase.masashi.a2@daiichisankyo.co.jp](mailto:kawase.masashi.a2@daiichisankyo.co.jp)  
Daiichi Sankyo Co., Ltd.  
+81 3 6225 1126 (office)

---

#### Reference

<sup>1</sup> DOE (Dividend on Equity): Total dividend amount / Equity attributable to owners of the company